V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015729 | 160007788 | 1.65 | 68.2 | Palliative (P) | 2016-11-04 | 2016-11-29 | ETOPOSIDE + RITUXIMAB | N | N | CTD | 101762522 |
| 160015730 | 160007789 | 1.8 | 61.1 | Neo-adjuvant (N) | 2018-12-21 | 2018-12-21 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100000895 |
| 160015732 | 160007790 | 1.6 | 88.7 | Palliative (P) | 2019-04-25 | 2019-04-25 | Carboplatin + Paclitaxel (3 weekly) | null | N | CARBOPLATIN + PACLITAXEL | 100872779 |
| 160015739 | 160007791 | 1.59 | 57.5 | Neo-adjuvant (N) | 2018-05-20 | 2018-05-20 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100125940 |
| 160015740 | 160007792 | 0 | 17.8 | Palliative (P) | 2019-11-01 | 2019-11-20 | Doxorubicin + Ifosfamide | 02 | N | LIPOSOMAL DOXORUBICIN | 100638111 |
| 160015741 | 160007793 | 1.67 | 184 | Palliative (P) | 2019-08-05 | 2019-08-05 | CARBOPLATIN + PACLITAXEL | 02 | null | CARBOPLATIN + PACLITAXEL | 101135079 |
| 160015743 | 160007794 | 0 | 0 | Palliative (P) | 2019-10-04 | 2019-10-05 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 101075311 |
| 160015744 | 160007795 | 1.78 | 75.2 | Palliative (P) | 2019-01-08 | 2019-01-14 | DOXORUBICIN | null | N | DOXORUBICIN | 101633964 |
| 160015745 | 160007796 | 1.81 | 67.8 | Curative (C) | 2019-03-19 | 2019-03-26 | Doxorubicin 75mg/m2 | Y | N | DOXORUBICIN | 100977969 |
| 160015746 | 160007797 | 1.6 | 75 | Palliative (P) | 2020-12-17 | 2021-01-04 | CARBOPLATIN + PACLITAXEL | N | N | CARBOPLATIN + PACLITAXEL | 101622762 |
| 160015747 | 160007798 | 0 | 19.1 | Palliative (P) | 2016-10-08 | 2016-10-19 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100561282 |
| 160015749 | 160007799 | 1.76 | 79.1 | Neo-adjuvant (N) | 2019-12-26 | 2019-12-29 | EW EuroEwing 2012 Arm A VAC | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101212494 |
| 160015750 | 160007800 | 1.67 | 74.8 | null | null | 2018-05-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101263802 |
| 160015751 | 160007801 | 1.85 | 82 | Palliative (P) | 2019-03-07 | 2019-03-07 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | N | LIPOSOMAL DOXORUBICIN | 100714421 |
| 160015752 | 160007802 | 1.67 | 113 | Palliative (P) | null | 2019-09-29 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 101544954 |
| 160015754 | 160007803 | 1.64 | 79.4 | Palliative (P) | 2016-06-29 | 2016-07-13 | Doxorubicin 75mg/m2 | 2 | N | DOXORUBICIN | 101572277 |
| 160015755 | 160007804 | 1.51 | 106.4 | Palliative (P) | 2018-06-15 | 2018-06-16 | Carboplatin + Paclitaxel (3 weekly) | 99 | null | CARBOPLATIN + PACLITAXEL | 100305949 |
| 160015756 | 160007805 | 1.87 | 87.3 | Neo-adjuvant (N) | 2017-03-30 | 2017-05-05 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101804720 |
| 160015757 | 160007806 | 1.73 | 74.2 | Palliative (P) | 2019-07-06 | 2019-07-07 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100425329 |
| 160015758 | 160007807 | 1.65 | 70 | Palliative (P) | 2018-05-22 | 2018-05-28 | CARBOPLATIN + PACLITAXEL | null | N | CARBOPLATIN + PACLITAXEL | 101541692 |
| 160015760 | 160007808 | 1.89 | 46.8 | Palliative (P) | 2019-05-04 | 2019-05-30 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101630052 |
| 160015761 | 160007809 | 0 | 75.1 | Curative (C) | 2019-01-27 | 2019-01-27 | ICON8B TRIAL | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100995533 |
| 160015763 | 160007810 | 1.77 | 72.5 | Neo-adjuvant (N) | 2016-10-08 | 2016-10-20 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101282548 |
| 160015766 | 160007811 | 1.67 | 67.2 | Curative (C) | null | 2019-02-11 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 100518805 |
| 160015767 | 160007812 | null | null | Palliative (P) | 2019-03-09 | 2019-03-12 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 100634929 |
| 160015768 | 160007813 | 1.79 | 75.2 | Adjuvant (A) | 2016-06-03 | 2016-06-03 | MELPHALAN | N | N | CISPLATIN + DOXORUBICIN | 100538248 |
| 160015769 | 160007814 | null | 75.6 | null | 2017-12-10 | 2017-12-22 | Carboplatin + Paclitaxel (3 weekly) | 02 | null | CEDIRANIB | 101344878 |
| 160015771 | 160007815 | 1.69 | 63.2 | null | 2021-10-04 | 2021-10-12 | Carboplatin + Paclitaxel (3 weekly) | N | N | CARBOPLATIN + PACLITAXEL | 101650294 |
| 160015772 | 160007816 | 1.64 | 70 | Palliative (P) | 2016-10-29 | 2016-10-30 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 100283352 |
| 160015773 | 160007817 | 0 | 0 | Palliative (P) | 2019-04-19 | 2019-04-25 | Liposomal Doxorubicin (Caelyx) | 02 | N | VIDE | 101161304 |
| 160015774 | 160007818 | 1.75 | 72.5 | Palliative (P) | 2017-12-25 | 2018-01-02 | PACLITAXEL | N | N | DOXORUBICIN + IFOSFAMIDE | 100906307 |
| 160015775 | 160007819 | 1.67 | 63.2 | Palliative (P) | 2019-11-29 | 2019-12-16 | null | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101406357 |
| 160015776 | 160007820 | 1.63 | 91.75 | Curative (C) | 2019-10-18 | 2019-10-19 | CAPECITABINE + RT | 2 | null | DOCETAXEL + GEMCITABINE | 100072120 |
| 160015778 | 160007821 | 0 | 17 | Adjuvant (A) | 2017-01-26 | 2017-01-26 | ETOP 13-18 BEAT-meso Trial | N | N | LIPOSOMAL DOXORUBICIN | 100509930 |
| 160015781 | 160007822 | 1.66 | 72.1 | Palliative (P) | 2018-10-30 | 2018-10-31 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 101746497 |
| 160015782 | 160007823 | 1.54 | 59.8 | Palliative (P) | 2019-06-12 | 2019-06-25 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100247291 |
| 160015784 | 160007824 | 1.73 | 80.7 | Neo-adjuvant (N) | 2016-05-16 | 2016-05-31 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | TRIAL | 100096206 |
| 160015785 | 160007825 | 0 | 45 | Palliative (P) | 2018-03-11 | 2018-04-01 | Carboplatin AUC 2 - 5 | 02 | N | CISPLATIN + PEMETREXED | 101672543 |
| 160015786 | 160007826 | 1.73 | 106.1 | Palliative (P) | 2019-09-07 | 2019-09-09 | Doxorubin 50mg/m2 | 02 | N | LIPOSOMAL DOXORUBICIN | 101725765 |
| 160015789 | 160007827 | 1.81 | 66.3 | Palliative (P) | 2016-11-06 | 2016-11-09 | Doxorubicin + Olaratumab | 02 | N | LIPOSOMAL DOXORUBICIN | 100124778 |
| 160015791 | 160007828 | 1.74 | 72.7 | Palliative (P) | 2017-08-15 | 2017-09-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101717290 |
| 160015792 | 160007829 | 1.52 | 79.6 | Palliative (P) | 2016-08-17 | 2016-08-21 | DOXORUBICIN | 02 | N | DOXORUBICIN | 100183563 |
| 160015793 | 160007830 | 1.63 | 86 | Palliative (P) | 2017-08-01 | 2017-08-24 | Carboplatin + Paclitaxel (3 weekly) | 02 | null | TRIAL UNSPECIFIED | 101401613 |
| 160015794 | 160007831 | 1.58 | 53.7 | Neo-adjuvant (N) | 2018-07-18 | 2018-07-26 | NB HRNBL-1 ch14.18/CHO only (trial) | N | N | DOXORUBICIN + IFOSFAMIDE | 100547941 |
| 160015797 | 160007832 | 1.79 | 52.2 | Curative (C) | null | null | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101605779 |
| 160015799 | 160007833 | 1.7 | 69.4 | Palliative (P) | 2016-10-18 | 2016-10-30 | DOXORUBICIN | 02 | N | DOXORUBICIN | 100988419 |
| 160015800 | 160007834 | 1.57 | 82 | Palliative (P) | 2017-01-10 | 2017-01-12 | Trial Unspecified | N | N | DOXORUBICIN + IFOSFAMIDE | 101350380 |
| 160015802 | 160007835 | 1.76 | 69.7 | Palliative (P) | 2016-07-31 | 2016-08-19 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100149944 |
| 160015806 | 160007836 | 1.66 | 82 | Palliative (P) | 2016-02-20 | 2016-02-26 | IBRUTINIB | N | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100832487 |
| 160015807 | 160007837 | 1.56 | 60.1 | Palliative (P) | 2019-08-06 | 2019-08-13 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100864853 |